Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

Diabetes, Obesity & Metabolism
R ScottSitagliptin Study 801 Group

Abstract

To assess the addition of sitagliptin to ongoing metformin therapy in patients with type 2 diabetes who were inadequately controlled [haemoglobin A(1c) (HbA(1c)) 7-11%] on metformin monotherapy. Patients (n = 273) on metformin (>/=1500 mg/day) were randomized to receive the addition of once-daily placebo, sitagliptin 100 mg or rosiglitazone 8 mg in a 1 : 1 : 1 ratio for 18 weeks. The efficacy analysis was based on the all-patients-treated population using an analysis of co-variance with change in HbA(1c) from baseline as the primary endpoint. The mean baseline HbA(1c) was 7.7% for the entire cohort. After 18 weeks, both active add-on therapies led to greater improvements in HbA(1c) from baseline: -0.73% for sitagliptin (p < 0.001 vs. placebo) and -0.79% for rosiglitazone compared with -0.22% for placebo. No difference was observed between the sitagliptin and rosiglitazone treatments (0.06% [95% confidence interval (CI): -0.14 to 0.25]). The proportion of patients achieving an HbA(1c) < 7% was greater with sitagliptin (55%) and rosiglitazone (63%) compared with placebo (38%). Body weight increased from baseline with rosiglitazone (1.5 kg) compared with body weight reduction with sitagliptin (-0.4 kg) and placebo (-0.8 kg). The d...Continue Reading

References

Feb 7, 2001·JAMA : the Journal of the American Medical Association·V FonsecaA Salzman
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Silvio E Inzucchi
Apr 3, 2003·American Journal of Physiology. Endocrinology and Metabolism·Andrea TuraKarl Thomaseth
May 28, 2004·Expert Opinion on Pharmacotherapy·Stefano Del Prato, Laura Volpe
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Jan 27, 2005·Drugs·Andrew J Krentz, Clifford J Bailey
Mar 9, 2005·Endocrinology and Metabolism Clinics of North America·Matthew C Riddle
Nov 1, 2006·International Journal of Clinical Practice·A Barnett
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group

❮ Previous
Next ❯

Citations

May 16, 2009·Advances in Therapy·Carolyn F Deacon, Jens J Holst
Apr 23, 2013·Advances in Therapy·Andrea D Fass, Jennifer A Gershman
May 24, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Samuel S EngelBarry J Goldstein
Dec 24, 2010·Diabetes Technology & Therapeutics·Chidambarann SudhakaranViswanathan Mohan
Nov 22, 2011·Diabetes, Obesity & Metabolism·Katherine R GerraldD E Jonas
May 12, 2010·International Journal of Clinical Practice·T SeckUNKNOWN Sitagliptin Study 024 Group
Jan 5, 2013·Cardiovascular Diabetology·Samuel S EngelBarry J Goldstein
Apr 12, 2013·Cardiovascular Diabetology·Diethelm TschöpePetra-Maria Schumm-Draeger
Sep 2, 2010·Cardiovascular Diabetology·L Romayne Kurukulasuriya, James R Sowers
Jan 21, 2012·The Review of Diabetic Studies : RDS·Simona Cernea
Sep 17, 2013·Drug Design, Development and Therapy·Vinay S Eligar, Stephen C Bain
Jan 1, 2010·Drug, Healthcare and Patient Safety·Mary Elizabeth CoxJennifer B Green
Jul 28, 2011·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Giuseppe Derosa, Pamela Maffioli
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Karen BarnardJennifer B Green
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Radha AndukuriMarc Rendell
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Jonathan K Reynolds
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Bo Ahrén
Aug 27, 2009·Therapeutics and Clinical Risk Management·Joan KhooMichael Horowitz
Jun 14, 2013·Vascular Health and Risk Management·Helmut SteinbergSamuel S Engel
Apr 9, 2010·Indian Journal of Pharmaceutical Sciences·K G Seshadri, M H B Kirubha
Mar 26, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Paul CraddyK Ian Johnson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.